DBVT Key Statistics, Chart & Performance
The current stock price of DBVT is 21.26 USD. In the past month the price increased by 25.06%. In the past year, price increased by 416.02%.
DBVT Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to DBVT. When comparing the yearly performance of all stocks, DBVT is one of the better performing stocks in the market, outperforming 99.23% of all stocks.
DBVT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to DBVT. DBVT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
DBVT Financial Highlights
Over the last trailing twelve months DBVT reported a non-GAAP Earnings per Share(EPS) of -1.91. The EPS increased by 43.66% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -85.56% | ||
| ROE | -142.22% | ||
| Debt/Equity | 0.08 |
DBVT Forecast & Estimates
8 analysts have analysed DBVT and the average price target is 21.61 USD. This implies a price increase of 1.66% is expected in the next year compared to the current price of 21.26.
For the next year, analysts expect an EPS growth of -36.93% and a revenue growth -55.09% for DBVT
DBVT Ownership
DBVT Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.39 | 387.092B | ||
| AMGN | AMGEN INC | 17.06 | 198.053B | ||
| GILD | GILEAD SCIENCES INC | 17.07 | 185.32B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.48 | 116.409B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.91 | 80.573B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.82 | 43.76B | ||
| INSM | INSMED INC | N/A | 32.21B | ||
| NTRA | NATERA INC | N/A | 27.199B | ||
| BIIB | BIOGEN INC | 13.02 | 27.192B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.47 | 20.623B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About DBVT
Company Profile
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The company is headquartered in Chatillon, Auvergne-Rhone-Alpes and currently employs 109 full-time employees. The company went IPO on 2012-03-29. The firm's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. The company dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The firm's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The firm operates one subsidiary DBV Technologies Inc. in the United States.
Company Info
DBV TECHNOLOGIES SA-SPON ADR
Batiment IRO, 107 Av. de la Republique
Chatillon AUVERGNE-RHONE-ALPES 92120 FR
CEO: Daniel Tasse
Employees: 110
Phone: 33155427878
DBV TECHNOLOGIES SA-SPON ADR / DBVT FAQ
Can you describe the business of DBV TECHNOLOGIES SA-SPON ADR?
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The company is headquartered in Chatillon, Auvergne-Rhone-Alpes and currently employs 109 full-time employees. The company went IPO on 2012-03-29. The firm's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. The company dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The firm's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The firm operates one subsidiary DBV Technologies Inc. in the United States.
What is the current price of DBVT stock?
The current stock price of DBVT is 21.26 USD. The price decreased by -0.93% in the last trading session.
What is the dividend status of DBV TECHNOLOGIES SA-SPON ADR?
DBVT does not pay a dividend.
How is the ChartMill rating for DBV TECHNOLOGIES SA-SPON ADR?
DBVT has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the analyst forecast for DBVT stock?
8 analysts have analysed DBVT and the average price target is 21.61 USD. This implies a price increase of 1.66% is expected in the next year compared to the current price of 21.26.
How many employees does DBV TECHNOLOGIES SA-SPON ADR have?
DBV TECHNOLOGIES SA-SPON ADR (DBVT) currently has 110 employees.
What is DBV TECHNOLOGIES SA-SPON ADR worth?
DBV TECHNOLOGIES SA-SPON ADR (DBVT) has a market capitalization of 1.00B USD. This makes DBVT a Small Cap stock.